All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
On 26 November 2018, mogamulizumab, a humanized monoclonal antibody directed against the CC chemokine receptor 4 (CCR4), received marketing authorization from the European Medicines Agency (EMA) for the treatment of adult patients with previously treated cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) or Sézary syndrome (SS), who have received at least one prior systemic therapy.
The approval granted by the EMA was based on positive results from the international, open-label, randomized, controlled, phase III MAVORIC trial (NCT01728805) comparing mogamulizumab with vorinostat in patients with previously treated MF and SS. Mogamulizumab therapy resulted in superior investigator-assessed progression-free survival in the intent-to-treat population compared with vorinostat therapy (median 7.7 months [95% CI, 5.7–10.3] versus 3.1 months [95% CI, 2.9–4.1] respectively, P < 0.0001).
The phase III trial investigators concluded that mogamulizumab could provide a new, effective treatment for patients with MF and, importantly, for SS, a subtype that represents a major therapeutic challenge in CTCL.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox